Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in ...

Karman Space and Defense ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, ...

Karman Holdings Inc., a maker of integrated systems for space and defense programs backed by Trive Capital, has filed for an initial public offering.

Flowco Holdings Inc. ("Flowco"), a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry, today announced the closing of its initial ...

Evercore (NYSE:EVR) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ...

In a report released today, David Palmer from Evercore ISI maintained a Hold rating on Krispy Kreme (DNUT – Research Report), with a price target of $13.00. The company’s shares closed ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

Tidal Partners, a prominent player in mergers and acquisitions, recently announced the recruitment of investment banker Anand Sankaralingam from Evercore, according to confidential sources.

Sankaralingam, who joined Evercore in 2014 and is currently on gardening leave, will start his new role at Tidal Partners this month and focus on dealmaking in the software industry, the sources ...